A Study of HS-20122 in Patients With Advanced Solid Tumors

NCT06927570 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

1050

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: HS-20122

Sponsor

Hansoh BioMedical R&D Company